Company: EDSA
Filing Date: 2025-12-12
Form Type: 10-K
Source: 0001171843-25-007914
Chunk: 991

Company: Edesa Biotech, Inc.
Filing Date: 2025-12-12
Form: 10-K
Item: Item 7A
Chunk 991
---

			216,800

			(58,200
			)

			Permanent differences

			200,000

			147,000

			Share issuance cost booked through equity or capitalization

			(202,000
			)

			36,000

			Non-capital losses limitation - U.S.

			0

			0

			Other

			(19,000
			)

			(38,000
			)

			Change in valuation allowance

			1,715,000

			1,549,000

			Income tax (recovery) expense

			$
			800

			$
			800

Components of the net deferred tax asset or liability

Deferred taxes are provided as a result of temporary differences that arise due to the difference between the income tax values and the carrying amount of assets and liabilities. Approximate deferred tax assets and liabilities are as follows:

			September 30, 2025

			September 30, 2024

			Non-capital losses carried forward - Canada

			$
			17,270,000

			$
			15,547,000

			Non-capital losses carried forward - U.S.

			749,000

			742,000

			Research and development tax credits

			1,510,000

			1,504,000

			Share issuance and financing costs

			314,000

			381,000

			Right-of-use lease liabilities

			-

			5,000

			Other temporary differences

			21,000

			21,000

			Subtotal

			$
			19,864,000

			$
			18,200,000

			Less: valuation allowance

			(19,733,000
			)

			(18,074,000
			)

			Total net deferred tax assets

			$
			131,000

			$
			126,000

			Property and equipment

			$
			(3,000
			)
			 
			$
			(2,000
			)

			Right-of-use assets

			-

			(5,000
			)

			Grant Income receivable

			(129,000
			)